ISSN: 2710-0588

Clinical and Translational Evaluation of a Ratio-Defined CoQ10-d-alpha-Tocopherol-BioPerine Ternary System for Oral Cardiac Support

Jabar Yassine*, Gregg L. Semenza, DeShawn Carter

World Food Supplement Association, New York, USA

* Corresponding Author: info@wfsas.org

Abstract

Background: Oral coenzyme Q10 (CoQ10) supplementation is often limited by formulation-dependent absorption and variable clinical response. A ratio-defined ternary system combining CoQ10, d-alpha-tocopherol, and BioPerine was developed to improve oral delivery and redox availability. Methods: This manuscript integrates the formulation-platform dataset and comparative rat-study results retained in the source material with published human studies directly relevant to CoQ10 exposure, antioxidant coupling, endothelial function, heart failure, and acute cardiac outcomes. Results: In the retained preclinical dataset, myocardial reduced CoQ10 increased 1.79-2.13-fold relative to a comparator lacking vitamin E, whereas plasma total CoQ10 increased 1.19-1.38-fold. In healthy volunteers, piperine coadministration increased CoQ10 exposure by approximately 30% after 21 days. In cardiovascular studies, CoQ10 supplementation improved exercise capacity, endothelial function, and several heart-failure endpoints in multiple trials, although one HFpEF pilot study was neutral. The strongest long-term signal came from Q-SYMBIO, in which major adverse cardiovascular events were 15% with CoQ10 versus 26% with placebo over two years. Conclusions: The formulation logic of the ternary system is consistent with published human evidence on exposure enhancement and cardiovascular bioenergetics. However, the exact ternary composition still requires a dedicated confirmatory randomized trial.

Keywords

CoQ10; coenzyme Q10; piperine; BioPerine; d-alpha-tocopherol; vitamin E; heart failure; endothelial function; oral bioavailability; randomized trial.

1. Introduction

CoQ10 is a lipid-phase redox cofactor central to mitochondrial electron transport and membrane antioxidant defense. In cardiovascular disease, reduced circulating or tissue CoQ10 has repeatedly been associated with impaired energetics, oxidative stress, and poorer functional status. At the same time, clinical supplementation studies have shown heterogeneous efficacy, and a substantial part of that variability is likely to be formulation dependent.

The ternary system evaluated here addresses three linked barriers: low oral absorption of crystalline CoQ10, vulnerability of the redox-active pool during gastrointestinal and post-absorptive transport, and high inter-individual variability in systemic exposure. In this formulation concept, CoQ10 functions as the central mitochondrial cofactor, d-alpha-tocopherol stabilizes the lipid phase and interacts with the ubiquinol/ubiquinone cycle, and piperine serves as a bioavailability enhancer. These ingredients are deployed across softgel, SMEDDS, and orally disintegrating micro-tablet platforms.

ISSN: 2710-0588

Rather than claiming de novo clinical trial findings for the exact ternary composition, this manuscript evaluates whether its formulation logic is supported by the available evidence. To do so, it places the retained formulation and comparative preclinical data alongside published human studies on CoQ10 exposure, antioxidant coupling, endothelial biology, and cardiovascular outcomes, thereby providing a clinically grounded translational assessment.

2. Materials and Methods

2.1. Formulation platforms and retained preclinical dataset

The retained engineering dataset describes three dosage-form platforms and a comparative rat study against a binary CoQ10-plus-piperine comparator. The formulation ratio window was CoQ10:vitamin E:piperine = 100:(12-18):1. The SMEDDS platform reported a mean droplet size of 25.6 nm and a polydispersity index (PDI) of 0.128. The rat study compared plasma total CoQ10 and myocardial reduced CoQ10 after 7 days of oral administration.

Table 1. Dosage-form platforms and key engineering features.

Platform	Active ratio window	Representative ratio	Key excipients	Engineering value
Softgel (oil solution)	100:(12-18):1	100:15:1	MCT; ascorbyl palmitate	High oil loading, dose uniformity, and scalable softgel manufacturing
SMEDDS (nanoemulsifying)	100:(12-18):1	100:12:1	Olive/soy oils; RH40; propylene glycol; rosemary extract	Nano-dispersion with mean droplet size 25.6 nm and PDI 0.128
OD micro-tablet (solidified lipid actives)	100:(12-18):1	100:18:1	Ethanol; porous silica; mannitol; crospovidone	Swallow-friendly solid form with rapid disintegration

Table 2. Rat comparison data from the retained preclinical benchmark.

Group	Plasma total CoQ10 (relative)	Myocardial reduced CoQ10 (relative)
Embodiment 1 (Softgel, 100:15:1)	1.26	2.13
Embodiment 2 (SMEDDS, 100:12:1)	1.38	1.87
Embodiment 3 (OD micro-tablet, 100:18:1)	1.19	1.79
Comparator (CoQ10 + BioPerine, no vitamin E)	1.00	1.00

2.2. Selection of published human clinical evidence

For the clinical evidence section, indexed human studies and trial reports were screened to address at least one of the following questions: whether piperine improves CoQ10 exposure; whether CoQ10 plus vitamin E shows measurable redox or antioxidant effects in humans; and whether CoQ10 supplementation improves cardiovascular, endothelial, or heart-failure outcomes. Priority was given to randomized, controlled, and decision-relevant datasets for tabulation.

ISSN: 2710-0588



Figure 1. Comparative rat-study outcomes for the ratio-defined ternary system and comparator.

3. Results

3.1. Preclinical signal of the ternary system

The retained preclinical evidence supports a formulation-specific redox hypothesis rather than a simple plasma-concentration hypothesis. Across the three ratio-defined dosage forms, plasma total CoQ10 increased modestly relative to the comparator, whereas myocardial reduced CoQ10 rose more strongly. This pattern suggests that vitamin E may help preserve or recycle the reduced CoQ10 pool in the tissue compartment most relevant to myocardial bioenergetics.

3.2. Human evidence for exposure enhancement and redox coupling

The published human literature aligns with the mechanistic logic of the formulation, although the evidence is component-resolved rather than based on the exact ternary combination. Badmaev and colleagues demonstrated that 5 mg piperine coadministered with 120 mg CoQ10 for 21 days increased the absolute plasma CoQ10 rise and area under the curve by approximately 30%, directly supporting the inclusion of BioPerine as an exposure enhancer. Kaikkonen and coworkers showed that CoQ10 plus d-alpha-tocopheryl acetate increased plasma CoQ10, raised plasma vitamin E, and shifted the ubiquinol proportion upward in marathon runners, indicating favorable redox handling, although hard performance benefits were not demonstrated in that setting. In a later statin-treated hypercholesterolemia cohort, the same group showed that CoQ10 and vitamin E do not behave as a uniformly additive pair; dose and matrix remain critical variables, as the combined arm attenuated the plasma Q10 rise while vitamin E dominated the ex vivo LDL oxidation signal.

ISSN: 2710-0588

Table 3. Human studies on exposure enhancement and antioxidant coupling relevant to the ternary design.

Study	Population / n	Intervention	Duration	Key clinical findings
Badmaev et al., 2000 [1]	Healthy men / 12	CoQ10 120 mg/day + piperine 5 mg/day vs CoQ10 + placebo	21 days	Absolute plasma rise: 1.12 vs 0.85 mg/L; AUC: 15.38 vs 11.81 mg/L-day; approximately 30% higher exposure with piperine.
Kaikkonen et al., 1998 [2]	Marathon runners / 37	CoQ10 90 mg + d-alpha-tocopheryl acetate 13.5 mg/day vs placebo	3 weeks	Plasma CoQ10 was 282% higher and vitamin E 16% higher before the run; the ubiquinol proportion increased, but muscular damage was not reduced.
Kaikkonen et al., 2000 [3]	Mild hypercholesterolemia on statins / 40	CoQ10 200 mg/day, vitamin E 700 mg/day, both, or placebo	3 months	Combined supplementation attenuated the plasma Q10 rise; vitamin E improved LDL oxidation resistance; Q10 increased the ubiquinol/total Q10 ratio.

Table 4. Human cardiovascular trials relevant to clinical translation of the ternary system.

Study	Population / n	Intervention	Duration	Key clinical findings
Hofman-Bang et al., 1995 [4]	Stable CHF / 79	CoQ10 100 mg/day vs placebo added to standard care	Two 3-month crossover periods	Maximal exercise capacity increased from 94 to 100 W during CoQ10; quality-of-life score improved from 107 to 113.
Tiano et al., 2007 [5]	Coronary artery disease / 38	CoQ10 300 mg/day vs placebo	1 month	Endothelium-dependent vasodilation, ecSOD activity, peak VO2, and O2 pulse improved significantly versus placebo.
Mortensen et al. (Q-SYMBIO), 2014 [6]	Moderate-to-severe HF / 420	CoQ10 100 mg three times daily vs placebo	2 years	Major adverse cardiovascular events: 15% vs 26%; cardiovascular mortality: 9% vs 16%; all-cause mortality: 10% vs 18%.
Samuel et al., 2022 [7]	HFpEF / 39	CoQ10 vs placebo	4 months	No significant between-group differences in diastolic indices or NT-proBNP.
Singh et al., 1998 [8]	Acute MI / 144	CoQ10 120 mg/day vs placebo	28 days	Angina, arrhythmias, poor left-ventricular function, and total cardiac events were all lower in the CoQ10 arm.
Bodea et al., 2025 [9]	Heart failure / 120	CoQ10 120 mg/day vs placebo	6 months	NT-proBNP was lower at endpoint, 6-minute walk distance was greater, and GLS improved in the CoQ10 arm.

ISSN: 2710-0588

3.3. Human cardiovascular outcome studies

The cardiovascular efficacy literature is stronger for CoQ10 overall than for the exact ternary combination. In chronic heart failure, the crossover trial by Hofman-Bang et al. showed modest improvements in exercise capacity and quality of life, whereas Q-SYMBIO later provided a larger and clinically more important long-term signal, with reductions in major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality. At the vascular level, Tiano et al. reported improvements in endothelium-dependent vasodilation, extracellular superoxide dismutase activity, and exercise-related parameters after 300 mg/day CoQ10. In acute myocardial infarction, Singh et al. reported fewer cardiac events and less oxidative stress after 28 days of CoQ10. More recent evidence is mixed rather than uniformly positive: the 2022 HFpEF pilot trial was neutral, whereas a 2025 heart-failure randomized controlled trial again reported improvements in NT-proBNP, global longitudinal strain, and 6-minute walk distance.

4. Discussion

Taken together, the evidence supports a measured translational conclusion. Available indexed human evidence is not sufficient to claim that the exact ratio-defined CoQ10-d-alpha-tocopherol-BioPerine system has already demonstrated clinical superiority in patients. What the evidence does show is a coherent chain of support: piperine can raise CoQ10 exposure, CoQ10 plus vitamin E can influence circulating redox markers, and CoQ10 itself has repeatedly shown cardiovascular signals in controlled human trials.

This pattern matters because the retained preclinical dataset does not merely show a formulation that raises total plasma CoQ10. It shows a formulation that preferentially amplifies myocardial reduced CoQ10 relative to a comparator lacking vitamin E. That feature is mechanistically plausible in light of the known coupling between ubiquinol and tocopherol radicals and helps explain why a ternary oral system could outperform a binary exposure-enhancement strategy.

Several limitations remain. First, the indexed clinical literature is richer for CoQ10 alone than for the exact ternary composition. Second, the combined vitamin E-plus-CoQ10 literature is not uniformly additive, which means that the ratio window and dosage form should be treated as critical design variables rather than promotional details. Third, piperine is pharmacologically active and may alter the absorption or metabolism of coadministered compounds; interaction monitoring should therefore be built into any confirmatory trial.

Accordingly, the next decisive step is a dedicated randomized, double-blind comparison of the exact ternary formulation against a high-quality standard CoQ10 control, with prespecified endpoints such as plasma CoQ10, redox ratio if analytically feasible, NT-proBNP, 6-minute walk distance, Kansas City Cardiomyopathy Questionnaire score, and adverse-event surveillance.

5. Conclusions

The ratio-defined CoQ10-d-alpha-tocopherol-BioPerine system combines a credible engineering rationale with a preclinical signal favoring myocardial reduced CoQ10 and a body of human evidence supporting the roles of CoQ10 exposure enhancement, redox coupling, and cardiovascular bioenergetics. Its clinical promise is therefore real but not yet definitively proven for the exact ternary composition. A formulation-specific randomized trial is now warranted.

ISSN: 2710-0588

References

[1] Badmaev V, Majeed M, Prakash L. Piperine derived from black pepper increases the plasma levels of coenzyme Q10 following oral supplementation. J Nutr Biochem. 2000;11(2):109-113. doi:10.1016/S0955-2863(99)00074-1.

[2] Kaikkonen J, Kosonen L, Nyyssonen K, et al. Effect of combined coenzyme Q10 and d-alpha-tocopheryl acetate supplementation on exercise-induced lipid peroxidation and muscular damage: a placebo-controlled double-blind study in marathon runners. Free Radic Res. 1998;29(1):85-92. doi:10.1080/10715769800300101.

[3] Kaikkonen J, Nyyssonen K, Tomasi A, et al. Antioxidative efficacy of parallel and combined supplementation with coenzyme Q10 and d-alpha-tocopherol in mildly hypercholesterolemic subjects: a randomized placebo-controlled clinical study. Free Radic Res. 2000;33(3):329-340. doi:10.1080/10715760000301501.

[4] Hofman-Bang C, Rehnqvist N, Swedberg K, Wiklund I, Astrom H. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. J Card Fail. 1995; 1(2): 101-107. doi:10.1016/1071-9164(95)90011-X.

[5] Tiano L, Belardinelli R, Carnevali P, et al. Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study. Eur Heart J. 2007; 28(18): 2249-2255. doi:10.1093/eurheartj/ehm267.

[6] Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014;2(6):641-649. doi:10.1016/j.jchf.2014.06.008.

[7] Samuel TY, Hasin T, Gotsman I, et al. Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: a prospective, randomized, double-blind, placebo-controlled trial. Drugs R D. 2022;22(1):25-33. doi:10.1007/s40268-021-00372-1.

[8] Singh RB, Wander GS, Rastogi A, et al. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc Drugs Ther. 1998;12(4):347-353. doi:10.1023/A:1007764616025.

[9] Bodea O, Boia ER, Craciun LM, et al. Effect of Coenzyme Q10 Supplementation on Cardiac Function and Quality of Life in Patients with Heart Failure: a randomized controlled trial. J Clin Med. 2025;14(11):3675. doi:10.3390/jcm14113675.

[10] Constantinescu R, McDermott MP, Dicenzo R, et al. A randomized study of the bioavailability of different formulations of coenzyme Q(10) (ubiquinone). J Clin Pharmacol. 2007;47(12):1580-1586. doi:10.1177/0091270007307571.

[11] Burke BE, Neuenschwander R, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South Med J. 2001; 94(11): 1112-1117. PMID:11780680.